Drug Profile

XH S004

Alternative Names: EXPD-101; XH-S004

Latest Information Update: 16 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

09 Oct 2025 Expedition Therapeutics plans a phase II trial in Chronic obstructive pulmonary disease (PO)
11 Aug 2025 Expedition Therapeutics in-licenses XH S004 from Shanghai Fosun Pharmaceutical for the treatment of Bronchiectasis and Chronic obstructive pulmonary disease
16 May 2025 S-INFINITY Pharmaceuticals plans a phase II trial in Bronchiectasis in China (PO, Tablets) (NCT06981091)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com